ClinicalTrials.gg
WithdrawnNCT04875442MEMOWAVEUpdated Oct 24, 2023

Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions

An interventional study of Memowave emitting sounds and Memowave not emitting sounds in Sleep Disorder, sponsored by BioSerenity. Withdrawn at 1 site in France. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by BioSerenity · Not applicable, Interventional, and Other

Why this study was withdrawn
PROJECT STOPPED
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

Safety and performance study of the MemoWave electroencephalographic and sound recording device to increase slow brain waves during sleep to improve memory consolidation in subjects with mild cognitive impairment

Read the detailed description

24 subjects aged between 40 and 85 years, presenting a mild cognitive disorder of the amnesic type (ie a memory complaint, a Mini Mental State ≥ 24 and a score ≤26 on free recall or ≤45 / 48 on total recall of the RLRI16 test) will be included;

Each patient spends 3 polysomnography nights at hospital: 1 night of habituation without Memowave device and next 2 nights with Memovave.

The device emits sounds to increase slow brain waves but Memowave emits sounds during only one of the two nights of test (night placebo vs night "verum"). The attribution of the night is randomized.

02

Conditions studied

  • Sleep Disorder

Browse trials for

03

In context

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.

Browse Sleep Wake Disorders studies →

Lead sponsor

BioSerenity is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject presenting a mild cognitive disorder of the amnesic type, defined by a memory complaint, a Mini Mental State ≥ 24 and a score ≤26 on free recall or ≤45 / 48 on total recall) of the RLRI16 episodic verbal memory test
  • At least 7 years of schooling

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric pathology
  • Known neurological pathology
  • High risk of apnea syndrome defined by at least 2 positive categories (each with a score ≥2) on the Berlin Questionnaire for Apnea Syndrome Screening
  • High risk of behavioral disorder in REM sleep defined by an RBDSQ score> 5.
  • Taking sleeping pills or antidepressants
  • Severe heart disease or unbalanced diabetes
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Memowave emitting sound

    Patients worn Memowave during one night, and the device emits sounds to increase slow brain signals

    Device: Memowave emitting sounds

  • Placebo comparator
    Memowave not emitting sound

    Patients worn Memowave during one night, and the device doesn't emit sounds

    Device: Memowave not emitting sounds

Interventions

  • DeviceMemowave emitting sounds

    Memowave is worn during one night and emits sounds to increase slow brain waves

  • DeviceMemowave not emitting sounds

    Memowave is worn during one night and doesn't emit sounds

06

What researchers measure

Primary outcomes

  1. accuracy of Electroencephalography signals of Memowave

    number of slow waves of Memomave divided by number of slow waves of Gold standard should be under 1

    Time frame: 3 days

Secondary outcomes

  1. Quality of the sleep

    Score of 1 to 4 (where 4 is a good sleep and 1 a very bad sleep)

    Time frame: 3 days

  2. efficiency on mnesic consolidation

    memory grid .More the score is high, more the efficiency is better

    Time frame: 3 days

  3. efficiency on mnesic consolidation

    scale WAIS (Weschler Adult Intelligence scale). The score should be more than 100.

    Time frame: 3 days

07

Study locations

1 site
  • ICM
    Paris, 75013, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2023; primary completion for Dec 2026, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2020
First posted
May 6, 2021
StartEst.
Oct 30, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04875442
Lead sponsor
BioSerenity
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Oct 30, 2023 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion